10.30.25 -- Inside A Micro-CRO's Evolution

Clinical medical writing for gene therapy regulatory documents is a demanding, detail-oriented task that diverges significantly from medical writing for more traditional therapies.

This expert panel explores how Australia, Taiwan, and South Korea provide a strategic advantage in conducting early, mid, and late-phase oncology trials.

Learn how to prepare CMC documentation that meets regulatory expectations, and explore key elements for a successful Pre-IND submission to avoid common delays in the review process.

Choosing the right clinical packaging and supply chain partner to support APAC studies can vary significantly based upon which countries are involved and the types of services required.

Anshul Gupte Ph.D., RAC Drugs, VP of Pharmaceutical Development, discusses phase-appropriate development, technical hurdles, building agile teams, and planning strategy for novel therapies.

Sujata (Suzzy) Bhavekar, M.S, CSM, shares how SGS's Hudson facility can enhance your drug development process by providing cutting-edge bioanalytical testing solutions and global support.

Learn how an innovative development platform with the unique ability to fully integrate DDI studies accelerate timelines and improve the likelihood of downstream success.

Biotech innovation is redefining the future of healthcare — but translating breakthroughs into patient impact requires the right partner.

Accelerate your biotech trials in Australia—cut costs by up to 60%, enroll patients in as little as 4–6 weeks, and generate FDA- and EMA-accepted data with no IND required.

Learn why functional outsourcing is important in today's clinical development environment and how Catalyst Flex supports this and is scalable to flex to your changing needs.

Ophthalmic drug and device development demands precision, agility, and deep therapeutic knowledge. Discover how our focused ophthalmology expertise can support your next clinical breakthrough.